BIOS Capital Management, LP insider trades: Actuate Therapeutics (ACTU) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where BIOS Capital Management, LP reports to the SEC
and 1 more company
Open-market buys and sales
54 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 27, 2025 | ACTU | ↑ Buy | 71,428 | $7.00 | $500K | Directly held by Bios 2024 Co-Invest, LP | Jun 30, 2025 (3d) |
| Jun 13, 2025 | LTRN | ↓ Sell | 14,218 | $3.09 | $44K | By Bios Fund II QP, LP | Jun 13, 2025 (0d) |
| Jun 13, 2025 | LTRN | ↓ Sell | 12,319 | $3.09 | $38K | By Bios Fund I, LP | Jun 13, 2025 (0d) |
| Jun 13, 2025 | LTRN | ↓ Sell | 7,206 | $3.09 | $22K | By Bios Fund I QP, LP | Jun 13, 2025 (0d) |
| Jun 13, 2025 | LTRN | ↓ Sell | 4,354 | $3.09 | $13K | by Bios Fund II, LP | Jun 13, 2025 (0d) |
| Jun 13, 2025 | LTRN | ↓ Sell | 1,903 | $3.09 | $6K | By Bios Fund II NT, LP | Jun 13, 2025 (0d) |
| Jun 12, 2025 | LTRN | ↓ Sell | 21,900 | $3.38 | $74K | By Bios Fund II QP, LP | Jun 13, 2025 (1d) |
| Jun 12, 2025 | LTRN | ↓ Sell | 18,976 | $3.38 | $64K | By Bios Fund I, LP | Jun 13, 2025 (1d) |
| Jun 12, 2025 | LTRN | ↓ Sell | 11,099 | $3.38 | $38K | By Bios Fund I QP, LP | Jun 13, 2025 (1d) |
| Jun 12, 2025 | LTRN | ↓ Sell | 6,706 | $3.38 | $23K | By Bios Fund II, LP | Jun 13, 2025 (1d) |
| Jun 12, 2025 | LTRN | ↓ Sell | 2,932 | $3.38 | $10K | By Bios Fund II NT, LP | Jun 13, 2025 (1d) |
| May 29, 2025 | LTRN | ↓ Sell | 19,990 | $2.99 | $60K | By Bios Fund II QP, LP | May 29, 2025 (0d) |
| May 29, 2025 | LTRN | ↓ Sell | 17,320 | $2.99 | $52K | By Bios Fund I, LP | May 29, 2025 (0d) |
| May 29, 2025 | LTRN | ↓ Sell | 10,131 | $2.99 | $30K | By Bios Fund I QP, LP | May 29, 2025 (0d) |
| May 29, 2025 | LTRN | ↓ Sell | 6,121 | $2.99 | $18K | By Bios Fund II, LP | May 29, 2025 (0d) |
| May 29, 2025 | LTRN | ↓ Sell | 2,675 | $2.99 | $8K | By Bios Fund II NT, LP | May 29, 2025 (0d) |
| Aug 14, 2024 | ACTU | ↑ Buy | 375,000 | $8.00 | $3.0M | Directly held by Bios Clinical Opportuni | Aug 14, 2024 (0d) |
| Aug 14, 2024 | ACTU | ↑ Buy | 125,000 | $8.00 | $1.0M | Directly held by Bios 2024 Co-Invest, LP | Aug 14, 2024 (0d) |
| Aug 14, 2024 | ACTU | ↓ Sell | 17,361 | $9.00 | $156K | Directly held by Bios Fund II QP, LP | Aug 14, 2024 (0d) |
| Aug 14, 2024 | ACTU | ↓ Sell | 5,314 | $9.00 | $48K | Directly held by Bios Fund II, LP | Aug 14, 2024 (0d) |
| Aug 14, 2024 | ACTU | ↓ Sell | 2,324 | $9.00 | $21K | Directly held by Bios Fund II NT, LP | Aug 14, 2024 (0d) |
| May 24, 2024 | LTRN | ↓ Sell | 20,832 | $6.30 | $131K | By Bios Fund II QP, LP | May 28, 2024 (4d) |
| May 24, 2024 | LTRN | ↓ Sell | 6,379 | $6.30 | $40K | By Bios Fund II, LP | May 28, 2024 (4d) |
| May 24, 2024 | LTRN | ↓ Sell | 2,789 | $6.30 | $18K | By Bios Fund II NT, LP | May 28, 2024 (4d) |
| Feb 29, 2024 | LTRN | ↓ Sell | 100,025 | $4.70 | $470K | By Bios Fund II QP, LP | Feb 29, 2024 (0d) |
| Feb 29, 2024 | LTRN | ↓ Sell | 30,585 | $4.70 | $144K | By Bios Fund II, LP | Feb 29, 2024 (0d) |
| Feb 29, 2024 | LTRN | ↓ Sell | 13,390 | $4.70 | $63K | By Bios Fund II NT, LP | Feb 29, 2024 (0d) |
| Jan 17, 2024 | LTRN | ↓ Sell | 40,893 | $4.20 | $172K | By Bios Fund II QP, LP | Jan 19, 2024 (2d) |
| Jan 17, 2024 | LTRN | ↓ Sell | 12,521 | $4.20 | $53K | By Bios Fund II, LP | Jan 19, 2024 (2d) |
| Jan 17, 2024 | LTRN | ↓ Sell | 5,475 | $4.20 | $23K | By Bios Fund II NT, LP | Jan 19, 2024 (2d) |
| Nov 29, 2023 | LTRN | ↓ Sell | 91,708 | $3.44 | $315K | By Bios Fund I, LP | Dec 1, 2023 (2d) |
| Nov 29, 2023 | LTRN | ↓ Sell | 53,640 | $3.44 | $185K | By Bios Fund I QP, LP | Dec 1, 2023 (2d) |
| Jun 21, 2023 | AZTR | ↑ Buy | 456,412 | $5.00 | $2.3M | Directly held by Bios Fund III QP, LP | Jun 23, 2023 (2d) |
| Jun 21, 2023 | AZTR | ↑ Buy | 73,708 | $5.00 | $369K | Directly held by Bios Fund III NT, LP | Jun 23, 2023 (2d) |
| Jun 21, 2023 | AZTR | ↑ Buy | 69,880 | $5.00 | $349K | Directly held by Bios Fund III, LP | Jun 23, 2023 (2d) |
| Dec 12, 2022 | INAB | ↑ Buy | 75,001 | $2.48 | $186K | Indirect | Dec 13, 2022 (1d) |
| Nov 28, 2022 | CGTX | ↑ Buy | 12,220 | $2.65 | $32K | By Bios Fund III QP, LP | Nov 29, 2022 (1d) |
| Nov 28, 2022 | CGTX | ↑ Buy | 1,973 | $2.65 | $5K | By Bios Fund III NT, LP | Nov 29, 2022 (1d) |
| Nov 28, 2022 | CGTX | ↑ Buy | 1,871 | $2.65 | $5K | By Bios Fund III, LP | Nov 29, 2022 (1d) |
| Nov 16, 2022 | CGTX | ↑ Buy | 54,009 | $1.40 | $76K | By Bios Fund III QP, LP | Nov 17, 2022 (1d) |
| Nov 16, 2022 | CGTX | ↑ Buy | 8,722 | $1.40 | $12K | By Bios Fund III NT, LP | Nov 17, 2022 (1d) |
| Nov 16, 2022 | CGTX | ↑ Buy | 8,269 | $1.40 | $12K | Bios Fund III, LP | Nov 17, 2022 (1d) |
| Nov 15, 2022 | CGTX | ↑ Buy | 1,141,030 | $1.20 | $1.4M | By Bios Fund III QP, LP | Nov 16, 2022 (1d) |
| Nov 15, 2022 | CGTX | ↑ Buy | 184,270 | $1.20 | $221K | By Bios Fund III NT, LP | Nov 16, 2022 (1d) |
| Nov 15, 2022 | CGTX | ↑ Buy | 174,700 | $1.20 | $210K | Bios Fund III, LP | Nov 16, 2022 (1d) |
| Nov 8, 2022 | LTRN | ↓ Sell | 132,575 | $4.40 | $583K | By Bios Fund II QP, LP | Nov 9, 2022 (1d) |
| Nov 8, 2022 | LTRN | ↓ Sell | 100,380 | $4.40 | $442K | By Bios Fund I, LP | Nov 9, 2022 (1d) |
| Nov 8, 2022 | LTRN | ↓ Sell | 58,711 | $4.40 | $258K | By Bios Fund I QP, LP | Nov 9, 2022 (1d) |
| Nov 8, 2022 | LTRN | ↓ Sell | 40,586 | $4.40 | $179K | By Bios Fund II, LP | Nov 9, 2022 (1d) |
| Nov 8, 2022 | LTRN | ↓ Sell | 17,748 | $4.40 | $78K | By Bios Fund II NT, LP | Nov 9, 2022 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ACTU insiders
Open-market trades in the last 12 months
About BIOS Capital Management, LP's insider trades
BIOS Capital Management, LP is a director at Actuate Therapeutics (ACTU). Since Aug 16, 2022, it has reported 19 open-market purchases worth $13.1M and 35 sales worth $3.9M on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include grants and awards (8 filings), other transactions (8 filings), conversions (4 filings), option exercises (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACTU insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.